Diabetes Complications
Conditions
Keywords
epinephrine, counterregulation, dose responses
Brief summary
Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. The specific aim of our study will be to determine the dose response effects of the key ANS counterregulatory hormone epinephrine on endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans.
Interventions
DRUGEpinephrine
Dose response of epinephrine infusion
OTHERSaline infusion
Placebo
Sponsors
Vanderbilt University
University of Maryland, Baltimore
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy controls age 18-55 yr. * Body mass index \>21 kg · m-2
Exclusion criteria
* Pregnant or breastfeeding women * Subjects unwilling or unable to comply with approved contraception measures * Subjects unable to give voluntary informed consent * Subjects on anticoagulant drugs, anemic or with known bleeding diatheses * Subjects with a history of severe, uncontrolled hypertension, heart disease, cerebrovascular incidents * Current tobacco use * Subjects with any known allergies to any of the study medications being used Physical Exam
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Flow mediated dilation (FMD) of the brachial artery | From baseline (pre glucose clamp) to end of experiment (time 240 minutes- 2 hours post intervention (glucose clamp)) | Measurements of FMD will be taken at baseline (pre intervention) and end of glucose clamp (post intervention) and the maximal % change determined |
Countries
United States
Outcome results
None listed